Entopharm

Entopharm is a South Korean biotechnology company specializing in the development of therapeutic agents and functional materials derived from insect resources. The company leverages its proprietary platform to identify and extract bioactive compounds from insects, such as the white-spotted flower chafer (Protaetia brevitarsis), to treat chronic inflammatory diseases, liver cirrhosis, and thrombotic disorders. Entopharm's pipeline includes candidates for non-alcoholic steatohepatitis (NASH) and gout, aiming to provide novel alternatives to traditional synthetic pharmaceuticals through natural, insect-based biopharmaceuticals. The company focuses on the scientific validation of traditional insect-based remedies, transforming them into standardized, high-value medical materials. Their research emphasizes the unique peptides and metabolites found in the insect immune system as a source for next-generation drug discovery.